



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

**INFORMATION DISCLOSURE STATEMENT
BY APPLICANT**

Application No: 09/601,644
Filing Date: 08/04/2000
First Named Inventor: Gariépy
Group Art Unit:
Examiner Name: Wallace, V.
Attorney Docket No.: MMC.P-001

Page 1 of 1

Examiner's Initials	US Patent Document	Name of Patentee or applicant of cited document	Date of Publication of Cited Document	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear
	5,310,663	DOBELI, ET AL	10 MAY 1994	
	5,047,513	DOBELI ET AL.	10 SEP 1991	
	5,571,698	LADNER ET AL.	05 NOV 1996	

FOREIGN PATENT DOCUMENTS

Examiner's Initials	Cite No.	office	Number	Kind Code	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document	Pages where relevant passages appear	T*

mm

11/22/04



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

INFORMATION DISCLOSURE STATEMENT
BY APPLICANT

Application No: 09/601,644
Filing Date: 08/04/2000
First Named Inventor: Gariépy
Group Art Unit:
Examiner Name: Wallace, V.
Attorney Docket No.: MMC.P-001

Page 1 of 2

Examiner's Initials	US Patent Document	Name of Patentee or applicant of cited document	Date of Publication of Cited Document	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear
------------------------	-----------------------	--	--	---

FOREIGN PATENT DOCUMENTS

Examiner's Initials	Cite No.	office	Number	Kind Code	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document	Pages where relevant passages appear	T*

mm

11/22/04



Examiner's Initials	OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS
<i>my</i>	SKEHAN, PHILIP, et al., New Colorimetric Cytotoxicity Assay for Anticancer-Drug Screening, Articles, Vol. 82, No. 13, July 4, 1990, pp 1107-1112.
<i>my</i>	KUBOTA, M.D., TETSURO, et al., Colorimetric Chemosensitivity Testing Using Sulforhodamine B, Journal of Surgical Oncology 52:83-88 (1993).
<i>my</i>	DEGRANDIS, STEPHANIE, et al., Globotetraosylceramide Is Recognized by the Pig Edema Disease Toxin, The Journal of Biological Chemistry, Vol. 264, No. 21, July 26, 1989, pp. 12520-12525.
<i>my</i>	KEUSCH, GERALD T., ET AL., Globotriaosylceramide, Gb3, Is an Alternative Functional Receptor for Shiga-like Toxin 2e, Infection and Immunity, Mar. 1995, p. 1138-1141.

This Information Disclosure Citation List is being submitted as a substitute for Form PTO-1449. The Examiner is requested to place his or her initials on the lines adjacent to the citations to indicate that the reference has been considered. The Examiner is further requested to fill in his or her name and the date the information was considered in blocks at the bottom of this substitute for Form PTO-1449.

Examiner *my* Date Considered 11/22/04

+

+

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Complete if Known

Application Number	09/601,644
Filing Date	August 4, 2000
First Named Inventor	Garipey, t al
Group Art Unit	
Examiner Name	
Attorney Docket Number	MMC P-001

(use as many sheets as necessary)

Sheet	1	of	6	Attorney Docket Number	MMC.P-001
-------	---	----	---	------------------------	-----------

RECEIVED

JAN 04 2001

TECH CENTER 1800/2800

U.S. PATENT DOCUMENTS

[illegible]

FOREIGN PATENT DOCUMENTS

[illegible]

**Examiner
Signature**

my


Date
Considered

11/22/04

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.**



ATTORNEY DOCKET NO. MMC.P-001
PATENT APPLICATION
November 16, 2000

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED

JAN 04 2001

TECH CENTER 1600/2500

Application No. 09/601,644
Filing Date: August 4, 2000
First Named Inventor: Gariépy, et al
Attorney Docket No. MMC.P-001


Page 2 of 6

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner's Initials	Cite No.		
ms		T. IIDA ET AL.: "A single amino acid substitution of Escherichia coli enterotoxin affects its oligomer formation" J. BIOL. CHEM., vol. 265, no. 24, 25 August 1989, pages 14065-14070,	
		C. CLARK ET AL.: "Phenylalanine 30 plays an important role in receptor binding of verotoxin-1" MOLECULAR MICROBIOL., vol. 19, no. 4, February 1996, pages 891-899,	
		G.J. TYRELL ET AL.: "Alteration of the carbohydrate binding specificity of verotoxins from Gal(alpha)1-4Gal to GalNAc(beta)1-3Gal(alpha)1-4Gal and vice versa by site-directed mutagenesis of the binding subunit " PROC. NATL. ACAD. SCI., vol. 89, January 1992, pages 524-528,	


ms

11/22/04



me	<p>J.D. MERMES ET AL.: "A reliable method for random mutagenesis: the generation of mutant libraries using spiked oligonucleotide primers" GENE, vol. 84, 1989, pages 143-151,</p>
	<p>G. DEL RÍO ET AL.: "Combinatorial libraries of proteins: Analysis of efficiency of mutagenesis techniques" BIOTECHNIQUES, vol. 17, no. 6, 1994, pages 1132-1139,</p>
	<p>A.A. KHINE AND C.A. LINGWOOD: "Capping and receptor-mediated endocytosis of cell-bound verotoxin (Shiga-like toxin) 1: Chemical identification of an amino acid in the B subunit necessary for efficient receptor glycolipid binding and cellular internalization" J. CELL PHYSIOL., vol. 161, no. 2, November 1994, pages 319-332,</p>
✓	<p>P.-G. NYHOLM ET AL.: "Two distinct binding sites for globotriaosyl ceramide on verotoxins: Identification by molecular modelling and confirmation using deoxy analogues and a new glycolipid receptor for all verotoxins" CHEMISTRY AND BIOLOGY, vol. 3, no. 4, April 1996, pages 263-275,</p>

11/22/04



<p>Ms</p>		<p>---</p> <p>L.P. PERERA ET AL.: "Identification of three amino acids residues in the B subunit of Shiga toxin and Shiga-like toxin type II that are essential for holotoxin activity"</p> <p>J. BACTERIOL., vol. 173, no. 3, February 1991, pages 1151-1160, XP002096325</p> <p>AM. SOC. MICROBIOL., BALTIMORE, US; cited in the application see the whole document</p>
		<p>D.J. BAST ET AL.: "Toxicity and immunogenicity of a verotoxin 1 mutant with reduced globotriaosylceramide receptor binding in rabbits"</p> <p>INFECTION AND IMMUNITY, vol. 65, no. 6, June 1997, pages 2019-2028, XP002096326</p> <p>ASM, WASHINGTON, DC, US see the whole document</p> <p>---</p>
		<p>M.P. JACKSON ET AL.: "Functional analysis of the Shiga toxin and Shiga-like toxin type II variant binding site subunits by using site-directed mutagenesis"</p> <p>J. BACTERIOL., vol. 172, no. 2, February 1990, pages 653-658, XP002096328</p> <p>AM. SOC. MICROBIOL., BALTIMORE, US; see the whole document</p>
<p>MS</p>		<p>S.W. LINDGREN ET AL.: "The specific activities of Shiga-like toxin type II (SLT-II) and SLT-II related toxin of enterohemorrhagic Escherichia coli differ when measured by vero cell cytotoxicity but not by mouse lethality"</p> <p>INFECTION AND IMMUNITY, vol. 62, no. 2, February 1994, pages 623-631, XP002096327</p> <p>ASM, WASHINGTON, DC, US see the whole document</p>

MS

11/22/04



Examiner's Cite
Initials No.


T

<i>Mu</i>	<p>BRAY, M. R. ET AL: "Expression of the Shiga-like toxin I receptor CD77 on human breast carcinomas, follicular lymphomas and multiple myelomas and absence of expression on CD34+ human hematopoietic cells: Implications for tumor cell purging." PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH ANNUAL MEETING, (MARCH, 1998) VOL. 39, PP. 63. MEETING INFO.: 89TH ANNUAL MEETING OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH NEW ORLEANS, LOUISIANA, USA MARCH 28-APRIL 1, 1998 AMERICAN , XP002096336 Abstract no. 429;</p>
	<p>BRAY, M. R. ET AL: "Shiga-like toxin as a template for the development of anti-breast cancer agents." PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH ANNUAL MEETING, (MARCH, 1998) VOL. 39, PP. 62-63. MEETING INFO.: 89TH ANNUAL MEETING OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH NEW ORLEANS, LOUISIANA, USA MARCH 28-APRIL 1, 1998 AMERIC, XP002096335 Abstract no. 428;</p>
	<p>P.G. NYHOLM ET AL.: "Modelling of the interaction of verotoxin-1 (VT1) with its glycolipid receptor. globotriaosylceramide (Gb3)" INT. J. BIOL. MACROMOL., vol. 17, no. 3-4, June 1995, pages 199-204,</p>
<i>✓</i>	<p>P.E. STEIN ET AL.: "Crystal structure of the cell-binding B oligomer of verotoxin-1 from E.coli" NATURE, vol. 355, 20 February 1992, pages 748-750, XP002096334 MACMILLAN JOURNALS LTD., LONDON,UK cited in the application see the whole document</p>

Mu

11/22/04

Examiner's Cite
Initials No.



<p>Aug</p>	<p>H. LING ET AL.: "Structure of the Shiga-like toxin I B-pentamer complexed with an analogue of its receptor Gb3" BIOCHEMISTRY, vol. 37, 17 February 1998, pages 1777-1788,</p>

ms 11/27/04